ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Psoriasis

Psoriasis

In this slideshow, we review the biologics currently approved to treat adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.

(Psoriasis ©ChristineLangerPueschel/Shutterstock.com)

The U.S. Food and Drug Administration has approved brodalumab (Siliq) for the treatment of adults and moderate-to-severe plaque psoriasis.

Psoriasis (©Artemidapsy/Shutterstock.com)

Axial disease seems to increasingly depend on the presence of skin psoriasis and HLA-B*27 alleles, researchers write in ARD.

Psoriasis (©Hriana/Shutterstock.com)

New treatment guidelines for plaque psoriasis have been issued in the U.S. where 50 percent of patients say they are dissatisfied with treatment.

Up to 30% of psoriasis patients will develop psoriatic arthritis. Studies show that a proportion of patients in clinical care have undiagnosed PsA.

Researchers reporting at the American Society of Hematology annual meeting this week say there is a link between a treatment for autoimmune disease and the development of leukemia.

Researchers find that apremilast and CF101 both are safe and effective for psoriasis, but apremilast outperforms CF101 through 16 weeks, until it plateaus.

Pages

Subscribe to Psoriasis on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.